Drug Trial Radar · NCT05990738
DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
69
Actual
Start
Feb 14, 2024
Primary completion
Mar 30, 2027
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Aug 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with extensive stage small cell lung cancer. The study is in people with advanced cancer that had previously received platinum-based chemotherapy and are eligible to receive a single agent chemotherapy treatment. The purpose of this study is to find the highest dose of BI 764532 that people can tolerate when taken together with a single agent chemotherapy. BI 764532 is an antibody-like molecule that may help the immune system fight cancer. Participants may continue to take BI 764532 as long as they benefit from treatment and can tolerate it. During this time, participants visit the study site regularly. The visits also depend on the response to the treatment. At the study visits, the doctors check the health of the participants, take necessary laboratory tests, and note any health problems that could have been caused by the study treatment.
Conditions
- Small Cell Lung Carcinoma (SCLC)
Interventions
BI 764532Drug
BI 764532
TopotecanDrug
Topotecan
Single agent chemotherapyDrug
single agent chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Occurrence of dose limiting toxicities (DLTs) in the maximum tolerated dose (MTD) evaluation periodTime frame: up to 9 weeks
- Part B: Occurrence of DLTs during the on-treatment periodTime frame: up to 36 months
- Part B: Occurrence of AEs during the on-treatment periodTime frame: up to 36 months
Locations
14 sites in 5 countries. Site status is shown where the registry gives one.
MedStar Georgetown University Hospital
Washington D.C., District of Columbia
Mayo Clinic - Florida
Jacksonville, Florida
University of Miami
Miami, Florida
Virginia Commonwealth University
Richmond, Virginia
INS Curie
Paris, France
HOP Civil
Strasbourg, France
Institut Gustave Roussy
Villejuif, France
Universitätsklinikum Carl Gustav Carus Dresden
Dresden, Germany
Universitätsklinikum Erlangen
Erlangen, Germany
Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg
Heidelberg, Germany
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Mainz, Germany
Universitätsklinikum Würzburg AÖR
Würzburg, Germany
Polish Mother's Memorial Hospital - Research Institute
Lodz, Poland
Leicester Royal Infirmary
Leicester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.